Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus

Moderna’s very large year to date surge on the back of fresh cancer vaccine data has turned mRNA oncology from a niche science story into front-page investing debate, and that kind of sudden spotlight often creates both excitement and blind spots. When a theme heats up this fast, some investors worry about arriving late while others fear chasing hype. This piece walks through 3 stocks exposed to the same news catalyst, helping you separate compelling oncology and mRNA vaccine stories from those that may not fit your risk appetite right now.

The stocks covered next are just a starting sample, and the full screen on Simply Wall St surfaced 54 more oncology and mRNA vaccine developers with equally compelling stories that are not discussed here. To identify, analyze, and prioritize your highest conviction ideas in this space, head straight into the Oncology & mRNA Vaccine Developers screener.

Moderna (MRNA)

Moderna is the clearest pure mRNA oncology story in this screen, with its cancer vaccine work now moving from concept to late stage reality and reshaping how investors think about what an mRNA medicines platform can support beyond COVID-era demand.

Moderna, Inc. develops mRNA medicines across vaccines and therapeutics, with all reported revenue of about US$2.2b coming from its biotechnology segment and a market value near US$85.3b highlighting its scale within oncology and mRNA vaccine developers.

"The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth."

What really matters now is how one unresolved assumption around future pricing power and uptake shapes where that growth ultimately lands.

That unresolved pricing and uptake question sits at the core of the full narrative for Moderna, which maps how Moderna’s pipeline story could decouple from today’s COVID memory.

Arcturus Therapeutics Holdings (ARCT)

Arcturus Therapeutics plugs directly into the Oncology & mRNA Vaccine Developers theme through its self amplifying mRNA platforms, giving investors exposure to respiratory, liver and vaccine style programs that sit alongside, rather than copy, what Moderna is doing in cancer and infectious diseases.

Arcturus Therapeutics develops mRNA medicines for rare liver and respiratory diseases and vaccine style uses, earning about US$29 million from discovery, development and commercialization of these therapies and carrying a market value near US$358 million.

"In May 2025 the collaboration devolved into arbitration over Development Milestone Payments related to the KOSTAIVE Covid-19 vaccine approval in Europe. Following an FDA policy change in September 2025 the KOSTAIVE Covid-19 vaccine in the USA is considered “indefinitely delayed” by Arcturus Therapeutics."

What investors will watch closely now is how one unresolved partner relationship reshapes expectations for future funding terms and mRNA pipeline economics.

That tension around future deal terms is exactly what the full narrative for Arcturus Therapeutics Holdings unpacks, spotlighting how Arcturus Therapeutics could turn a messy dispute into a re-rated pipeline story.

Vaxcyte (PCVX)

Vaxcyte slots into the Oncology & mRNA Vaccine Developers theme as a pure-play vaccine developer, giving you exposure to late stage conjugate and protein vaccines rather than mRNA. The real story is now shifting to what its lead pneumococcal program can achieve.

Vaxcyte, Inc. is a US clinical stage vaccine developer focused on conjugate and novel protein vaccines for serious bacterial diseases, with no commercial revenue yet and a market value of about US$11.1b reflecting expectations around its pneumococcal and Group A Strep pipeline.

Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines. If successful, these programs could support future product approvals and create a path to commercial revenue.

What really moves the needle from here is how one yet to be tested assumption about future real world vaccine uptake plays out.

That uptake question is exactly what the full narrative for Vaxcyte digs into, setting out how Vaxcyte’s late stage vaccine story could accelerate or stall as real world data arrives.

Seeking Fresh Alternatives Beyond These Stocks

New themes break out fast. The best opportunities often fly before most investors notice. Scan fresh stock ideas while they are still under the radar and act while they remain less widely followed.

• Target resilient income ideas that can keep paying you even when momentum drops by filtering for 8 dividend fortresses built for staying power.
• Spot potential breakout compounders early by running the 20 high quality undiscovered gems before the crowd catches what is quietly building momentum.
• Track the picks supplying critical hardware behind AI momentum using the curated 92 AI infrastructure stocks while their stories are still being priced in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com